• TriSalus Life Sciences

  Participated · Series C · Dec 2015

  TriSalus Life Sciences develops a drug delivery platform that includes devices using its proprietary Pressure-Enabled Drug Delivery (PEDD) approach and a clinical-stage investigational immunotherapy, nelitolimod. The company has two FDA-cleared devices: the TriNav® Infusion System for hepatic arterial infusion to liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is designed to modulate pressure and flow to deliver more therapeutic to tumors while reducing undesired delivery to normal tissue. Nelitolimod is intended to treat the immunosuppressive tumor environment that can limit current immunotherapies, and patient data from Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects. TriSalus plans to study nelitolimod delivered by PEDD across several indications where TLR9 is expressed and mechanical delivery barriers exist. The company works in partnership with leading cancer centers to advance its technology and clinical programs. Following the recent financing, TriSalus expects its cash runway to extend through 2025. Surefire Medical develops, manufactures and markets targeted delivery devices for the Interventional Oncology market centered on its Surefire Infusion System (SIS), a microcatheter with an expandable tip that increases infusion pressure and blocks backflow. The SIS is designed to deliver significantly more therapy into tumors while protecting healthy tissue. Clinical data cited include a randomized trial showing 68% improved tumor uptake and 58% decreased non-target delivery, a registry reporting 68% complete tumor response and 92% objective response, and a retrospective comparison showing a 79% versus 37% objective response for HCC. The company plans to use new financing to expand sales and marketing in the U.S. and Europe, initiate sales and clinical trials in China, and complete the 170-patient randomized QED trial (NCT02748161). Surefire is also pursuing opportunities in the $66B immunotherapy market, targeting site-specific delivery to solid tumors. The company is based in Westminster, Colo. Surefire Medical develops infusion and direct-to-tumor delivery systems for the interventional radiology and interventional oncology markets. Its flagship device, Surefire Precision, is specifically designed for targeted delivery in the treatment of primary liver cancer (HCC). The company is commercial stage and has received regulatory approvals in the U.S., Europe, Canada, Australia, New Zealand, Taiwan, Mexico and Brazil. Founded in 2009 and led by President and CEO James Chomas, the company is based in Westminster, Colorado. Surefire plans to use the new funding to support the global launch of Surefire Precision. It closed a $15M Series C in February 2015 to fund those commercial expansion efforts. Surefire Medical develops infusion systems designed to deliver embolic agents through a microcatheter using an expandable tip that collapses in forward flow and expands to the vessel wall in reverse flow. Its product family includes the Surefire Infusion System (ST, LT, mT) and specialty catheters. The company is commercial-stage and its devices have received regulatory approvals in the U.S., Europe, Canada, Australia, New Zealand and Taiwan. Surefire intends to use the financing to expand product development, clinical trials, operations and marketing. The company was founded in 2009 and is led by CEO Jim Chomas. It is based in Westminster, Colorado.

• Wildflower Health

  Participated · Series A · Dec 2013

  Led by CEO Leah Sparks, Wildflower Health builds digital and value-based care solutions for obstetric providers and payers. Its platform helps providers evaluate and design value-based care (VBC) models, install digital health and point-of-care decision-support tools, and adapt workflows to VBC requirements. The company continuously processes clinical and financial data to surface real-time clinical metrics and to manage payments, reconciliations, and outcomes measurement. Its proprietary maternity bundle spans prenatal to postnatal care and accounts for the total cost of pregnancy for both mother and baby. Wildflower plans to use new funding to strengthen its internal team and to prepare for nationwide expansion of that maternity bundle. Providence has increased its financial commitment and expanded a contract to install Wildflower’s solution across Southern California. Wildflower Health is a San Francisco-based mobile health software company that connects families to health resources on their smartphones. Its tools promote healthy pregnancies, track family health, and support the growth of each family member based on individual health needs over time. The company launched its Family Health platform, an integrated application to manage pregnancy and family health. Over the past year it tripled its recurring license revenue and expanded its user base by more than 10x. Led by founder and CEO Leah Sparks, Wildflower plans to use new funding to continue organizational growth and expand its Family Health platform. Wildflower Health builds Due Date Plus, a mobile maternity program that functions as a patient-navigation tool configurable by health plans to show coverage details and in‑network providers. The app is HIPAA‑compliant and is used by payers including Aetna, LifeMap and state Medicaid programs such as Wyoming’s. The company plans to broaden its product portfolio into pediatrics and family health and will launch a Spanish version of Due Date Plus in the coming months. Wildflower also agreed to a strategic partnership with Everyday Health, operator of the What to Expect franchise that reaches about 75% of pregnant women in the U.S. The new funding will support strategic expansion and ongoing product development. Wildflower Health offers Due Date Plus, a mobile maternity program available on iOS and Android that uses self-reported data to identify high-risk pregnancies and drive interventions. The app delivers customized tools and content and refers users to care management programs. The company plans to expand its mobile health offering to health plans, self-insured employers and Medicaid clients using the new funding. Wildflower was founded in 2012 by CEO Leah Sparks and Kathy Bellevin. Prior to this round the company secured seed funding in late 2012 through Rock Health.

• FitBionic

  Led · Equity · Aug 2013

  FitBionic develops consumer-centered prosthetics, with its first commercial product the FitBionic Foot. The company emphasizes amputee wellness and targets the growing diabetic population. Development of the FitBionic Foot was supported by a $1.2 million NIH grant, and the product has won multiple design awards and national recognition. FitBionic combines designers, technologists, and entrepreneurs from leading bionics and prosthetics companies and is based in Boulder, Colorado. Management includes CEO Eythor Bender and founder/CTO Jerome Rifkin; investors are joining the board as the company scales. FitBionic is preparing a global launch of the FitBionic Foot and is using recent financing as a bridge to a planned Series A in 2014.

No current team members are available.